Genmab A/S passed its most significant milestone to date by obtaining its first drug approval, for ofatumumab (Arzerra) as a therapy for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and alemtuzumab (Campath). (BioWorld International)

Cytos Biotechnology AG lost almost one-third of its value Friday on news that its therapeutic vaccine for nicotine addiction failed to show efficacy in a Phase II study. (BioWorld International)

Prosensa Therapeutics BV is banking an up-front payment of £16 million (US$25.3 million) and could earn up to £412 million more from an RNA-based drug development alliance with GlaxoSmithKline plc in the X-linked neuromuscular disorder Duchenne's muscular dystrophy (DMD). (BioWorld International)